An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage

Nature Medicine

Volumn 20, Issue 5, 2014, Pages 548-554

  Newman, Aaron M ^a   Bratman, Scott V ^a,b   To, Jacqueline ^b   Wynne, Jacob F ^b   Eclov, Neville C W ^b   Modlin, Leslie A ^b   Liu, Chih Long ^a   Neal, Joel W ^a   Wakelee, Heather A ^a   Merritt, Robert E ^a   Shrager, Joseph B ^a   Loo, Billy W ^b   Alizadeh, Ash A ^a   Diehn, Maximilian ^a,b,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCULATING TUMOR DNA; DNA; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PERSONALIZED PROFILING BY DEEP SEQUENCING; CANCER SCREENING; DISEASE SEVERITY; DNA SEQUENCE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SOMATIC MUTATION; TUMOR BIOPSY; TUMOR VOLUME; VERY ELDERLY; BLOOD; CANCER STAGING; GENETICS; HIGH THROUGHPUT SEQUENCING; ISOLATION AND PURIFICATION; LUNG NON SMALL CELL CANCER; METABOLISM; NEOPLASM; TUMOR EMBOLISM;

CARCINOMA, NON-SMALL-CELL LUNG; DNA, NEOPLASM; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; NEOPLASM STAGING; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; TUMOR MARKERS, BIOLOGICAL;

EID: 84903218109     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3519     Document Type: Article

References (43)

1. Taniguchi, K. et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin. Cancer Res. 17, 7808-7815 (2011).
2. Rosell, R. et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361, 958-967 (2009).
3. Kuang, Y. et al. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin. Cancer Res. 15, 2630-2636 (2009).
4. Gautschi, O. et al. Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer Lett. 254, 265-273 (2007).
5. Leary, R.J. et al. Development of personalized tumor biomarkers using massively parallel sequencing. Sci. Transl. Med. 2, 20ra14 (2010).
6. McBride, D.J. et al. Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosom. Cancer 49, 1062-1069 (2010).
7. He, J. et al. IgH gene rearrangements as plasma biomarkers in non-Hodgkin's lymphoma patients. Oncotarget 2, 178-185 (2011).
8. Forshew, T. et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci. Transl. Med. 4, 136ra168 (2012).
9. Leary, R.J. et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci. Transl. Med. 4, 162ra154 (2012).
10. Narayan, A. et al. Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. Cancer Res. 72, 3492-3498 (2012).
11. Dawson, S.J. et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 368, 1199-1209 (2013).
12. Murtaza, M. et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108-112 (2013).
13. Crowley, E., Di Nicolantonio, F., Loupakis, F. & Bardelli, A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat. Rev. Clin. Oncol. 10, 472-484 (2013).
14. Forbes, S.A. et al. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 38, D652-D657 (2010).
15. Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075 (2008).
16. Youn, A. & Simon, R. Identifying cancer driver genes in tumor genome sequencing studies. Bioinformatics 27, 175-181 (2011).
17. Bergethon, K. et al. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol. 30, 863-870 (2012).
18. Kwak, E.L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
19. Pao, W. & Hutchinson, K.E. Chipping away at the lung cancer genome. Nat. Med. 18, 349-351 (2012).
20. Imielinski, M. et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107-1120 (2012).
21. Govindan, R. et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150, 1121-1134 (2012).
22. Koivunen, J.P. et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res. 14, 4275-4283 (2008).
23. Rikova, K. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190-1203 (2007).
24. Fan, H.C., Blumenfeld, Y.J., Chitkara, U., Hudgins, L. & Quake, S.R. Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc. Natl. Acad. Sci. USA 105, 16266-16271 (2008).
25. Su, Z. et al. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J. Mol. Diagn. 13, 74-84 (2011).
26. Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786-792 (2005).
27. Iyengar, P. & Timmerman, R.D. Stereotactic ablative radiotherapy for non-small cell lung cancer: rationale and outcomes. J. Natl. Compr. Canc. Netw. 10, 1514-1520 (2012).
28. Nesbitt, J.C., Putnam, J.B. Jr., Walsh, G.L., Roth, J.A. & Mountain, C.F. Survival in early-stage non-small cell lung cancer. Ann. Thorac. Surg. 60, 466-472 (1995).
29. Aberle, D.R. et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 365, 395-409 (2011).
30. Diehl, F. et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc. Natl. Acad. Sci. USA 102, 16368-16373 (2005).
31. Diehl, F. et al. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology 135, 489-498 (2008).
32. Chan, K.C. et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin. Chem. 59, 211-224 (2013).
33. Heitzer, E. et al. Tumor associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med. 5, 30 (2013).
34. Schmitt, M.W. et al. Detection of ultra-rare mutations by next-generation sequencing. Proc. Natl. Acad. Sci. USA 109, 14508-14513 (2012).
35. Shiroguchi, K., Jia, T.Z., Sims, P.A. & Xie, X.S. Digital RNA sequencing minimizes sequence-dependent bias and amplification noise with optimized single-molecule barcodes. Proc. Natl. Acad. Sci. USA 109, 1347-1352 (2012).
36. Quail, M.A. et al. Optimal enzymes for amplifying sequencing libraries. Nat. Methods 9, 10-11 (2012).
37. Oyola, S.O. et al. Optimizing Illumina next-generation sequencing library preparation for extremely AT-biased genomes. BMC Genomics 13, 1 (2012).
38. Fisher, S. et al. A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. Genome Biol. 12, R1 (2011).
39. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
40. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079 (2009).
41. Quinlan, A.R. & Hall, I.M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841-842 (2010).
42. Koboldt, D.C. et al. Var Scan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568-576 (2012).
43. Fisher, R.A. Statistical Methods for Research Workers (Oliver and Boyd, 1925).